These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 20592394)

  • 1. CA19-9 serum concentrations--analysis of the serum kinetics during first-line therapy of pancreatic cancer in relation to overall survival.
    Klapdor R; Bahlo M; Babinski A; Klapdor S
    Anticancer Res; 2010 May; 30(5):1869-74. PubMed ID: 20592394
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Further evidence for prolongation of survival of pancreatic cancer patients by efficacy orientated sequential polychemotherapy (EOSPC) based on serial tumor marker determinations (CA 19-9/CEA).
    Klapdor R; Bahlo M; Babinsky A
    Anticancer Res; 2005; 25(3A):1687-91. PubMed ID: 16033083
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reflections on treatment strategies for palliative chemotherapy of pancreatic cancer.
    Klapdor R; Bahlo M; Babinsky A; Brenzinger ML
    Anticancer Res; 2007; 27(4A):1789-94. PubMed ID: 17649774
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The clinical value of serum CEA, CA19-9, and CA242 in the diagnosis and prognosis of pancreatic cancer.
    Ni XG; Bai XF; Mao YL; Shao YF; Wu JX; Shan Y; Wang CF; Wang J; Tian YT; Liu Q; Xu DK; Zhao P
    Eur J Surg Oncol; 2005 Mar; 31(2):164-9. PubMed ID: 15698733
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Undetectable preoperative levels of serum CA 19-9 correlate with improved survival for patients with resectable pancreatic adenocarcinoma.
    Berger AC; Meszoely IM; Ross EA; Watson JC; Hoffman JP
    Ann Surg Oncol; 2004 Jul; 11(7):644-9. PubMed ID: 15197014
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum CA19-9 determination in the management of pancreatic cancer.
    van den Bosch RP; van Eijck CH; Mulder PG; Jeekel J
    Hepatogastroenterology; 1996; 43(9):710-3. PubMed ID: 8799418
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improvement of survival by efficacy orientated sequential polychemotherapy of exocrine pancreatic cancer.
    Klapdor R; Müller C; Seutter R; Bahlo M; Peters W; Fenner C
    Anticancer Res; 2000; 20(6D):5201-7. PubMed ID: 11326695
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The impact of resection margin status and postoperative CA19-9 levels on survival and patterns of recurrence after postoperative high-dose radiotherapy with 5-FU-based concurrent chemotherapy for resectable pancreatic cancer.
    Kinsella TJ; Seo Y; Willis J; Stellato TA; Siegel CT; Harpp D; Willson JK; Gibbons J; Sanabria JR; Hardacre JM; Schulak JP
    Am J Clin Oncol; 2008 Oct; 31(5):446-53. PubMed ID: 18838880
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Application of a time-varying covariate model to the analysis of CA 19-9 as serum biomarker in patients with advanced pancreatic cancer.
    Boeck S; Haas M; Laubender RP; Kullmann F; Klose C; Bruns CJ; Wilkowski R; Stieber P; Holdenrieder S; Buchner H; Mansmann U; Heinemann V
    Clin Cancer Res; 2010 Feb; 16(3):986-94. PubMed ID: 20103662
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased levels of both carbohydrate antigen 19-9 and duke pancreatic monoclonal antigen type 2 reflect postoperative prognosis in patients with pancreatic carcinoma.
    Shibata K; Iwaki K; Kai S; Ohta M; Kitano S
    Pancreas; 2009 Aug; 38(6):619-24. PubMed ID: 19436235
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CA 19-9 in evaluating the response to chemotherapy in advanced pancreatic cancer.
    Ishii H; Okada S; Sato T; Wakasugi H; Saisho H; Furuse J; Ishikawa O; Matsuno S; Yokoyama S
    Hepatogastroenterology; 1997; 44(13):279-83. PubMed ID: 9058159
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic impact of perioperative serum CA 19-9 levels in patients with resectable pancreatic cancer.
    Kondo N; Murakami Y; Uemura K; Hayashidani Y; Sudo T; Hashimoto Y; Nakashima A; Sakabe R; Shigemoto N; Kato Y; Ohge H; Sueda T
    Ann Surg Oncol; 2010 Sep; 17(9):2321-9. PubMed ID: 20336387
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CA19-9 as the most significant prognostic indicator of metastatic colorectal cancer.
    Wang WS; Lin JK; Chiou TJ; Liu JH; Fan FS; Yen CC; Lin TC; Jiang JK; Yang SH; Wang HS; Chen PM
    Hepatogastroenterology; 2002; 49(43):160-4. PubMed ID: 11941943
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sequential polychemotherapy in exocrine pancreatic cancer.
    Klapdor R; Bahlo M; Babinski A; Broemel T; Müller C; Seutter R
    Anticancer Res; 2003; 23(2A):841-4. PubMed ID: 12820310
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Value of combined therapy in pancreatic cancer with a poor prognosis: analysis of 233 clinical cases].
    Wang Y; Zhao P; Wang CF; Shan Y; Zhao DB; Tian YT; Sun YM; Che X; Zhang JW
    Zhonghua Yi Xue Za Zhi; 2009 Sep; 89(34):2381-5. PubMed ID: 20137689
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Which is the best monitoring study (tumor marker, computed tomography or 18F-fluoro-2-deoxy-D-glucose positron emission tomography) to evaluate efficacy of chemotherapy on unresectable pancreatic cancer ?].
    Kobayashi N; Fujita K; Fujisawa T; Takahashi H; Yoneda M; Abe Y; Inamori M; Kirikoshi H; Kubota K; Saito S; Nakajima A
    Gan To Kagaku Ryoho; 2008 Jan; 35(1):65-70. PubMed ID: 18195530
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A retrospective analysis of early CA19‑9 change in salvage chemotherapy for refractory pancreatic cancer.
    Nakai Y; Isayama H; Sasaki T; Takahara N; Hamada T; Uchino R; Mizuno S; Miyabayashi K; Yamamoto K; Mohri D; Kogure H; Yamamoto N; Hirano K; Ijichi H; Tateishi K; Tada M; Koike K
    Cancer Chemother Pharmacol; 2013 Dec; 72(6):1291-7. PubMed ID: 24121456
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase II trial of marimastat in advanced pancreatic cancer.
    Evans JD; Stark A; Johnson CD; Daniel F; Carmichael J; Buckels J; Imrie CW; Brown P; Neoptolemos JP
    Br J Cancer; 2001 Dec; 85(12):1865-70. PubMed ID: 11747327
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum markers in patients with resectable pancreatic adenocarcinoma: macrophage inhibitory cytokine 1 versus CA19-9.
    Koopmann J; Rosenzweig CN; Zhang Z; Canto MI; Brown DA; Hunter M; Yeo C; Chan DW; Breit SN; Goggins M
    Clin Cancer Res; 2006 Jan; 12(2):442-6. PubMed ID: 16428484
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detection of serum tumor markers in the diagnosis and treatment of patients with pancreatic cancer.
    Jiang XT; Tao HQ; Zou SC
    Hepatobiliary Pancreat Dis Int; 2004 Aug; 3(3):464-8. PubMed ID: 15313690
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.